Last reviewed · How we verify
SHR7280 simulant； Ganirelix Acetate Injection
SHR7280 simulant； Ganirelix Acetate Injection is a GnRH antagonist Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).
Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Used for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).
At a glance
| Generic name | SHR7280 simulant； Ganirelix Acetate Injection |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 3 |
Mechanism of action
Ganirelix competitively blocks GnRH receptors in the pituitary gland, rapidly suppressing gonadotropin release without an initial flare effect. This prevents premature LH surge during controlled ovarian hyperstimulation, allowing precise timing of oocyte retrieval in assisted reproductive procedures.
Approved indications
- Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)
Common side effects
- Injection site reactions (erythema, pain, bruising)
- Headache
- Abdominal pain
- Nausea
- Ovarian hyperstimulation syndrome (OHSS)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR7280 simulant； Ganirelix Acetate Injection CI brief — competitive landscape report
- SHR7280 simulant； Ganirelix Acetate Injection updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about SHR7280 simulant； Ganirelix Acetate Injection
What is SHR7280 simulant； Ganirelix Acetate Injection?
How does SHR7280 simulant； Ganirelix Acetate Injection work?
What is SHR7280 simulant； Ganirelix Acetate Injection used for?
Who makes SHR7280 simulant； Ganirelix Acetate Injection?
What drug class is SHR7280 simulant； Ganirelix Acetate Injection in?
What development phase is SHR7280 simulant； Ganirelix Acetate Injection in?
What are the side effects of SHR7280 simulant； Ganirelix Acetate Injection?
What does SHR7280 simulant； Ganirelix Acetate Injection target?
Related
- Drug class: All GnRH antagonist drugs
- Target: All drugs targeting GnRH receptor
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Reproductive Medicine / Fertility
- Indication: Drugs for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)
- Compare: SHR7280 simulant； Ganirelix Acetate Injection vs similar drugs
- Pricing: SHR7280 simulant； Ganirelix Acetate Injection cost, discount & access